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Abstract
Quantitative extraction of high-dimensional mineable data from med-
ical images is a process known as radiomics. Radiomics is foreseen as
an essential prognostic tool for cancer risk assessment and the quantifica-
tion of intratumoural heterogeneity. In this work, 1615 radiomic features
(quantifying tumour image intensity, shape, texture) extracted from pre-
treatment FDG-PET and CT images of 300 patients from four different
cohorts were analyzed for the risk assessment of locoregional recurrences
(LR) and distant metastases (DM) in head-and-neck cancer. Prediction
models combining radiomic and clinical variables were constructed via
random forests and imbalance-adjustment strategies using two of the four
cohorts. Independent validation of the prediction and prognostic per-
formance of the models was carried out on the other two cohorts (LR:
AUC = 0.69 and CI = 0.67; DM: AUC = 0.86 and CI = 0.88). Fur-
thermore, the results obtained via Kaplan-Meier analysis demonstrated
the potential of radiomics for assessing the risk of specific tumour out-
comes using multiple stratification groups. This could have important
clinical impact, notably by allowing for a better personalization of chemo-
radiation treatments for head-and-neck cancer patients from different risk
groups.
Preprint submitted to “Scientific Reports” on March 14, 2017
Introduction
Precision oncology promises to tailor the full spectrum of cancer care to an
individual patient, notably in terms of personalization of cancer prevention,
screening, risk stratification, therapy and response assessment. With sufficient
infrastructure support and concerted efforts from the different stakeholders, it
is possible to foresee that personalized therapy would become the standard of
care in oncology1. Cancer mechanisms are increasingly elucidated as functions
of different biomarkers or tumour genetic mutations, thereby changing the way
we design clinical trials to achieve better cancer management efficacy in spe-
cific patient sub-populations2. On the other hand, “rapid learning paradigms”
(i.e. knowledge-driven healthcare) consisting of reusing routine clinical data to
develop knowledge in the form of models that can predict treatment outcomes
for a larger portion of the population have also gained popularity in the oncol-
ogy community3,4. Although most research approaches to precision oncology
are centered on genomics technologies5,6, it is thought that only the integration
of multiple-omics, i.e., panomics data (genomics, transcriptomics, proteomics,
metabolomics, etc.) could efficiently unravel biological mechanisms7,8.
The importance of panomics integration for cancer risk assessment emerges
from the tremendous extent of heterogeneous characteristics expressed at mul-
tiple levels of tumours. Genes, proteins, cellular microenvironments, tissues
and anatomical landmarks within tumours exhibit considerable spatial and
temporal variations that could potentially yield valuable information about
tumour aggressiveness. Tumours are generally composed of multiple clonal
sub-populations of cancer cells forming complex dynamic systems that exhibit
rapid evolution as a result of their interaction with their microenvironment and
therapy perturbations9. Differing properties can be attributed to the different
sub-populations in terms of growth rate, expression of biomarkers, ability to
metastasize, and immunological characteristics10. These properties could be
described by differences in metabolic activity, cell proliferation, oxygenation
levels, pH, blood vasculature and necrotic areas observed within the tumour.
Such intratumoural differences are related to the concept of tumour heterogene-
ity, a characteristic that can be observed with significantly different extents
even amongst tumours of the same histopathological type. Tumours exhibiting
such heterogeneous characteristics are thought to be associated with high risk
of resistance to treatment, progression, metastasis or recurrence11–13.
Nowadays, medical imaging plays a central role in the investigation of in-
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tratumoural heterogeneity, as radiological images are acquired as routine prac-
tice for almost every patient with cancer. Medical images such as 2-deoxy-2-
[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) and X-ray
computed tomograph (CT) are minimally invasive and they carry an immense
source of potential data for decoding the tumour phenotype14. The quantitative
extraction of high-dimensional mineable data from all types of medical images
and whose subsequent analysis aims at supporting clinical decision-making is a
process coined with the term “radiomics”15–18. The demonstration that gene-
expression signatures and clinical phenotypes could be inferred from tumour
imaging features19–21 has led to an exponential growth of this field in the past
few years22,23. The underlying hypothesis of radiomics is that the genomic
heterogeneity of aggressive tumours could translate into heterogeneous tumour
metabolism and anatomy, thereby envisioning the quantitative analysis of diag-
nostic medical images as an essential prognostic tool for cancer risk assessment
and as an integral part of panomic tumour signature profiling.
The translation of radiomics analysis into standard cancer care to support
treatment decision-making involves the development of prediction models in-
tegrating clinical information that can assess the risk of specific tumour out-
comes24(Fig. 1). In this work, our main objective is to construct prediction
models using advanced machine learning to evaluate the risk of locoregional
recurrences and distant metastases prior to chemo-radiation of head-and-neck
(H&N) cancers, a group of biologically similar neoplasms originating from the
squamous cells that line the mucosal surfaces in the oral cavity, paranasal si-
nuses, pharynx or larynx. The locoregional control of H&N cancers is usually
good, but this is, however, not matched by improvements in survival, as the
development of distant metastases and second primary cancers are the leading
causes of treatment failure and death25,26. In order to improve patient survival
and outcomes, the importance of identifying relevant prognostic factors that
can better assess the aggressiveness of tumours at the moment of diagnosis is
crucial.
We hypothesize that radiomic features are important prognostic factors for
the risk assessment of specific H&N cancer outcomes27. The machine learning
strategy employed in this work involves the extraction of 1615 different radiomic
features from a total of 300 patients from four different institutions. Two cohorts
are used to construct the prediction models by combining radiomics (intensity,
shape, textures) and clinical attributes (patient age, H&N type, tumour stage)
via random forests classifiers and imbalance-adjustments of training samples,
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and the remaining two cohorts are reserved to evaluate the prediction (binary
assessment of outcome) and prognostic (time-to-event assessment) performance
of the corresponding models (Fig. 2). Throughout this study, results obtained
for locoregional recurrences and distant metastases are also compared against
prediction models constructed for the general risk assessment of overall survival
in H&N cancer. A comprehensive comparison of the prediction/prognostic per-
formance of radiomics versus clinical models and volumetric variables is also
performed. Our results suggest that the integration of radiomic features into
clinical prediction models has considerable potential for assessing the risk of
specific outcomes prior to treatment of H&N cancers. Accurate stratification
of locoregional recurrence and distant metastasis risks could eventually provide
a rationale for adapting the radiation doses and chemotherapy regimens that
the patients receive. Overall, combining quantitative imaging information with
other categories of prognostic factors via advanced machine learning could have
a profound impact on the characterization of tumour phenotypes and would
increase the possibility of translation of outcome prediction models into the
clinical environment as a means to personalize treatments.
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Figure 1. From radiomics analysis to treatment personalization. (a) Example
of diagnostic FDG-PET and CT images of two head-and-neck cancer patients with tumour
contours. The patient that did not respond well to treatment (right) has a more heteroge-
neous intratumoural intensity distribution in both FDG-PET and CT images than the patient
that responded well to treatment (left). (b) The radiomics analysis strategy involves the ex-
traction of features differentiating responders from non-responders to treatment. Features are
extracted from the FDG-PET and CT tumour contours and quantify tumour shape, intensity,
and texture. (c) Advanced machine learning combines radiomics features and patient clinical
information via a random forest algorithm. The classifier is trained to differentiate between
responders and non-responders to treatment (prediction model). (d) The output probability
of the random forest classifier computed on new patients can be used to assess the risk of non-
response to treatment via probabilities of occurrence of outcome events and time estimates.
Eventually, accurate risk assessment of specific tumour outcomes via radiomics analysis could
help to better personalize cancer treatments.
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Figure 2. Models construction strategy and analysis workflow. Four differ-
ent cohorts were used to demonstrate the utility of radiomics analysis for the pre-treatment
assessment of the risk of locoregional recurrence and distant metastases in head-and-neck
cancer. The H&N1 and H&N2 cohorts were combined and used as a single training set
(n = 194), whereas the H&N3 and H&N4 cohorts were combined and used as a single testing
set (n = 106). The best combinations of radiomics features were selected in the training set
using imbalance-adjusted logistic regression learning and bootstrapping validations. These
radiomics features were combined with selected clinical variables in the training set using
imbalance-adjusted random forest learning and stratified random sub-sampling validations.
Independent prediction analysis was performed in the testing set for all classifiers fully con-
structed in the training set. Independent prognosis analysis and Kaplan-Meier risk stratifica-
tion was carried out in the testing set using the output probability of occurrence of events of
random forests fully constructed in the training set. 6
Results
Summary of presentation of results
To ease reading and the understanding of this study, a summary of how results
are presented in the text is provided in Supplementary Fig. S1.
Association of variables with tumour outcomes
In order to assess the value of quantitative pre-treatment imaging to predict
specific cancer outcomes in H&N cancer, we performed a comprehensive uni-
variate analysis of the association of radiomic features with locoregional re-
currences (“LR” or “Locoregional”), distant metastases development (“DM” or
“Distant”) and overall survival (“OS” or “Survival” or “Death”). A total of 1615
radiomic features (Fig. 1b and Supplementary Methods section 2.5 for complete
description) were first extracted from the gross tumour volume (GTVprimary +
GTVlymph nodes) of the FDG-PET and CT images (Fig. 1a), for all 300 patients
from the four H&N cancer cohorts (Fig. 2): I) 10 first-order statistics features
(intensity); II) 5 morphological features (shape); and III) 40 texture features
each extracted using 40 different combinations of parameters. We also com-
pared these results to the predictive power of the tumour volume (“Volume”)
and of the following clinical variables: Age, T-Stage, N-Stage, TNM-Stage and
human papillomavirus status (HPV status), where HPV status was available for
120 of the 300 patients (Supplementary Tables S5-S8). The association of the
different variables with the different H&N cancer outcomes (binary endpoints)
was then analyzed using Spearman’s rank correlations (rs) computed on all pa-
tients, and significance was assessed by applying multiple testing corrections
using the Benjamini-Hochberg procedure28 with a false discovery rate of 10 %.
Overall, we found that 0 %, 63 % and 12 % of the total radiomic features
extracted from PET scans, and that 0 %, 61 % and 34 % of the total radiomic
features extracted from CT scans were significantly associated with LR, DM
and OS, respectively (after multiple testing corrections). The radiomic fea-
tures (PET or CT) with the highest associations with LR, DM and OS were
LZHGEGLSZM from CT scans (rs = −0.15, p = 0.007), ZSNGLSZM from CT
scans (rs = −0.29, p = 2 × 10−7) and GLVGLRLM from CT scans (rs = 0.24,
p = 4× 10−5), respectively (Supplementary Table S1). Tumour volume was not
found to be significantly associated with LR (rs = −0.04, p = 0.48), but was
significantly associated with DM (rs = 0.24, p = 3×10−5) and OS (rs = −0.18,
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p = 2 × 10−3). Finally, we found that {Age, T-Stage, N-Stage, HPV status},
{N-Stage} and {Age, T-Stage, HPV status} were significantly associated with
LR, DM and OS, respectively. The clinical variables with the highest associ-
ations with LR, DM and OS were HPV− (rs = 0.39, p = 8 × 10−6), higher
N-Stage (rs = 0.18, p = 1×10−3) and higher T-Stage (rs = 0.21, p = 3×10−4),
respectively (Supplementary Table S2).
Construction of prediction models
The construction of prediction models for LR, DM and OS was carried out using
a training set consisting of the combination of 194 patients from the H&N1 and
H&N2 cohorts (Fig. 2). Three initial radiomic feature sets were considered: I)
the 1615 radiomic features extracted from PET scans (“PET” feature set); II)
the 1615 radiomic features extracted from CT scans (“CT” feature set); and
III) a combined set containing all PET and CT radiomic features used in feature
sets I and II (“PETCT” feature set).
Prediction models consisting of radiomic information only were first con-
structed for each of the three H&N outcomes and the three initial radiomic
feature sets. Feature set reduction, feature selection, prediction performance es-
timation, choice of model complexity (Supplementary Fig. S2) and final model
computation processes were carried out using logistic regression and bootstrap
resampling, similarly to the methodology developed in the study of Vallie`res et
al.29 To account for the disproportion of occurrence of events and non-occurrence
of events in the training set (15 % LR, 13 % DM, 16 % deaths), an imbalance-
adjustment strategy adapted from the study of Schiller et al.30 was also applied
during the training process. Overall for the PET, CT and PETCT feature sets,
the number of variables forming the final radiomic models for each outcome
were, respectively: I) 8, 3 and 3 radiomic variables for the LR outcome; II) 6,
3 and 3 radiomic variables for the DM outcome; and III) 4, 3 and 6 radiomic
variables for the OS outcome.
The construction of prediction models combining radiomic and clinical vari-
ables was then carried out for the nine identified radiomic models (3 feature
sets × 3 outcomes). By estimating prediction performance via stratified ran-
dom sub-sampling in the training set, the following group of clinical variables
were first selected for each outcome: I) {Age, H&N type, T-Stage, N-Stage}
for LR prediction; II) {Age, H&N type, N-Stage} for DM prediction; and III)
{Age, H&N type, T-Stage, N-Stage} for OS prediction. Final prediction models
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were ultimately constructed for each radiomic feature set and H&N outcome by
combining the selected radiomic and clinical variables via random forests and
imbalance adjustments.
Performance of prediction models
The performance of the radiomic prediction models constructed using logistic
regression and of the prediction models constructed by combining radiomic and
clinical variables via random forests was validated in a testing set consisting of
the combination of 106 patients from the H&N3 and H&N4 cohorts (Fig. 2)
using receiver operating characteristic (ROC) metrics (binary endpoints).
Figure 3 presents the performance results (AUC: area under the ROC curve)
obtained in the testing set for the radiomics and radiomics + clinical mod-
els, where the significance of the increase in AUC when combining clinical to
radiomic variables is assessed using the method of DeLong et al.31. Sensitiv-
ity, specificity and accuracy of predictions are also presented in Supplementary
Fig. S3. Overall, it can be observed that there is a general increase in prediction
performance for most of the different categories of models that we constructed
in this work. For LR prediction, the increase in AUC is significant for predic-
tion models from the PET (p = 0.03) and the CT (p = 0.01) radiomic feature
sets. For DM prediction, none of the radiomics models show a significant AUC
increase when combined with clinical variables. For OS (death) prediction, the
increase in AUC is significant for prediction models from the PET (p = 0.01)
and the PETCT (p = 0.006) radiomic feature sets. Furthermore, we verified
that the increase in performance is not explained by the use of a more complex
and potentially more predictive learning algorithm: random forests classifiers
constructed with radiomic variables alone preserved the predictive properties
obtained by logistic regression models constructed with the same variables, but
without improving them (Supplementary Table S3). These results point to the
potential of random forests in successfully combining the complementary value
of different categories of prognostic factors such as radiomic and clinical vari-
ables.
In Fig. 3, the highest performance for LR prediction was obtained using the
model combining the PETCT radiomic and clinical variables, with an AUC
of 0.69. For DM prediction, the highest performance was obtained using the
CT radiomic model, with an AUC of 0.86. These results demonstrate that
different radiomic-based models could successfully be used to predict specific
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outcomes such as locoregional recurrences and distant metastases in H&N can-
cer. Finally, the highest performance for OS (death) prediction was obtained
using the model combining the PET radiomic and clinical variables, with an
AUC of 0.74. For subsequent analysis in the next section, only the prediction
models (radiomics and radiomics + clinical) constructed from these radiomic
features sets (PETCT for LR, CT for DM, PET for OS) are used. The com-
plete description of these identified radiomic models (specific features, texture
extraction parameters, logistic regression coefficients) is given in Supplementary
Results section 1.4.2.
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Figure 3. Prediction performance of selected models. All prediction models
were selected and built using the training set (H&N1 and H&N2; n = 194) for three initial
radiomic feature sets: I) PET radiomic features (PET ); II) CT radiomic features (CT ); and
III) PET and CT radiomic features (PETCT ). The prediction performance is evaluated here
in terms of the area under the receiver operating characteristic curve (AUC) for patients of
the testing set (H&N3 and H&N4; n = 106), for two types of prediction models: I) Radiomic
models constructed using logistic regression (Radiomics); and II) Radiomic models combined
with clinical variables via random forests (Radiomics + clinical). Significant increase in AUC
from Radiomics to Radiomics + clinical models is identified with an asterisk (*), and non-
significant increase is identified by “n.s.”. The radiomic feature sets providing the prediction
models with highest performance in this study are identified with an arrow for each outcome.
Comparison with other prognostic factors
The performance of the best radiomic prediction models and the best prediction
models combining radiomic and clinical variables identified in this study (shown
with arrows in Fig. 3) were further compared against other prognostic factors:
I) Volume; II) “clinical-only” models; III) combination of Volume and clinical
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variables; and IV) a validated radiomic signature developed for the prognosis
assessment of overall survival21,32. In addition to the prediction performance
evaluated using ROC metrics, the prognostic performance of the models was also
assessed using: I) the concordance index (CI)33 between the output probability
of occurrence of an event (LR, DM, death) of prediction models and the time
elapsed before an event occurred (“time-to-event”); and II) the p-value obtained
from Kaplan-Meier analysis using the log-rank test between two risk groups.
The models consisting of only radiomic or the Volume variables were optimized
using logistic or cox regression, and all models involving clinical variables were
optimized using random forest classifiers, still using the defined training set of
this work (H&N1 and H&N2 cohorts; n = 194). Fully independent results are
then presented in Table 1 for models evaluated in the testing set (H&N3 and
H&N4 cohorts; n = 106).
For locoregional recurrences, we found that the model combining the PETCT
radiomic and clinical variables provided the best performance in terms of pre-
dictive/prognostic power and balance of classification of occurrence of events
and non-occurrence of events, notably with an AUC of 0.69, a sensitivity of
0.63, a specificity of 0.68, an accuracy of 0.67, a CI of 0.67 and a Kaplan-Meier
p-value of 0.03. Using random permutation tests, each variable was calculated
to be approximately of equal importance in the random forest model (Supple-
mentary Table S4). Similarly to univariate analysis, Volume was not found to
be a significant prognostic factor for LR. On the other hand, clinical variables
alone had high performance with an AUC of 0.72 and a CI of 0.69, but this
type of modeling did not provide sufficient balance between the prediction of
occurrence and non-occurrence of events (sensitivity of 0.50, specificity of 0.76).
For distant metastases, we found that the model combining the CT radiomic
and clinical variables provided the best overall performance, notably with an
AUC of 0.86, a sensitivity of 0.86, a specificity of 0.76, an accuracy of 0.77, a
CI of 0.88 and a Kaplan-Meier p-value of 3×10−6. However, radiomic variables
were found to be of much higher importance than the clinical variables in the
random forest model (Supplementary Table S4). In fact, the model composed
of clinical variables alone did not perform well. Volume was again found to be
a significant prognostic factor for DM, but radiomic variables outperformed it.
For overall survival, we found that the model composed of clinical variables
alone provided the best overall performance, notably with an AUC of 0.78, a
sensitivity of 0.92, a specificity of 0.57, an accuracy of 0.65, a CI of 0.76 and
a Kaplan-Meier p-value of 3× 10−5. Furthermore, the H&N type variable had
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the highest and N-Stage the lowest importance in the model (Supplementary
Table S4). Another important finding was that Volume alone provided similar
or better prognosis assessment of OS than any of the following radiomic-based
models: I) the best radiomic model for OS constructed in this work; II) the
original radiomic signature using the cox regression coefficients employed in the
work of Aerts & Velazquez et al.21; and III) a revised version of the radiomic sig-
nature computation (Supplementary Section 2.6.2) using new sets of regression
coefficients trained with the current training set of this work.
Risk assessment of tumour outcomes
The work performed in this study leads to the identification of three prediction
models based on three final random forest classifiers, one for each of the out-
come studied here (identified with italic fonts in Table 1): I) {PET-GLNGLSZM,
CT-CorrelationGLCM , CT-LGZEGLSZM, age, H&N type, T-Stage, N-Stage} for
LR; II) {CT-LRHGEGLRLM, CT-ZSVGLSZM, CT-ZSNGLSZM, age, H&N type,
N-Stage} for DM; and III) {age, H&N type, T-Stage, N-Stage} for OS. A prop-
erty of a random forest is that the binary prediction of each of its decision
tree can be averaged to serve as an output probability of occurrence of a given
event (probRF). This output probability, similarly to other machine learning
algorithms, can constitute one of the tools to be used for the risk assessment of
specific tumour outcomes. For example, the final random forest classifiers con-
structed in the training set (H&N1 and H&N2 cohorts; n = 194) can be used to
stratify the risk of occurrence of the outcome events for each patient of the test-
ing set (H&N3 and H&N4 cohorts; n = 106) into three groups (Fig. 4a): I) low-
risk group → 0 ≤ probRF < 13 ; II) medium-risk group → 13 ≤ probRF < 23 ; and
III) high-risk group → 23 ≤ probRF < 1. Thereafter, this stratification scheme
can be used to evaluate the probability of non-occurrence of the events after
a given time for the different risk groups via Kaplan-Meier analysis. Standard
Kaplan-Meier analysis using two risk groups (probRF ≤ 0.5, probRF > 0.5) is
first shown in Fig. 4b for all patients of the testing set. These curves demonstrate
the possibility of prognostic risk assessment of specific outcomes in H&N cancer
such as locoregional recurrences (p = 0.03) and distant metastases (p = 3×10−6)
using specific prediction models combining different radiomic and clinical vari-
ables, but also of the general outcome of overall survival (p = 3× 10−5) using a
prediction model composed of clinical variables only. More accurate prognostic
risk assessment can then be further performed using Kaplan-Meier analysis with
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three risk groups (as defined above: low-risk, medium-risk, high-risk) as shown
in Fig. 4c for all patients of the testing set. For the risk assessment of LR, the
developed prediction model is, however, not powerful enough to significantly
separate the patients between the high/medium (p = 0.62) and medium/low
(p = 0.10) risk groups. In the case of DM, the developed prediction model al-
lows to significantly separate the patients between the high/medium (p = 0.05)
and medium/low (p = 0.03) risk groups. For OS, the developed prediction
model does not significantly separate the patients between the high/medium
risk groups (p = 0.07), but it does significantly separate the patients between
the medium/low risk groups (p = 0.02).
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Table 1. Comparison of prediction/prognostic performance of models con-
structed in this work with other variable combinations. Performance is shown
for models constructed in the training set (H&N1 and H&N2; n = 194) and indepen-
dently evaluated in the testing set (H&N3 and H&N4; n = 106).
Outcome Variables
Prediction Prognosis
AUCa Sensitivitya Specificitya Accuracya CIb p-valuec
Locoregional
RadiomicsPETCT 0.64 0.56 0.67 0.65 0.63 0.28
Volume 0.43 0.31 0.58 0.54 0.40 0.80
Clinical 0.72 0.50 0.76 0.72 0.69 0.05
RadiomicsPETCT + Clinical 0.69 0.63 0.68 0.67 0.67 0.03
Volume + Clinical 0.71 0.50 0.76 0.72 0.68 0.06
Distant
RadiomicsCT 0.86 0.79 0.77 0.77 0.88 0.0001
Volume 0.80 0.86 0.65 0.68 0.83 0.10
Clinical 0.55 0.64 0.46 0.48 0.60 0.61
RadiomicsCT + Clinical 0.86 0.86 0.76 0.77 0.88 0.000003
Volume + Clinical 0.78 1 0.50 0.57 0.80 0.0004
Survival
RadiomicsPET 0.62 0.58 0.66 0.64 0.60 0.03
Volume 0.68 0.67 0.57 0.59 0.67 0.29
Clinical 0.78 0.92 0.57 0.65 0.76 0.00003
RadiomicsPET + Clinical 0.74 0.79 0.57 0.62 0.71 0.002
Volume + Clinical 0.79 0.88 0.52 0.60 0.76 0.0006
Survivald
RadiomicsCTcompleteSign
e – – – – 0.66 0.70
RadiomicsCTsign
f 0.68 0.71 0.50 0.55 0.66 0.05
RadiomicsCTsign
g + Clinical 0.80 0.96 0.38 0.51 0.75 0.001
→ Models involving Radiomic variables only or the Volume variable only were optimized using
logistic/cox regression. All models involving Clinical variables were optimized using random
forests.
→ The best predictive/prognostic and balanced models for each outcome (final models) are
identified in italic and are fully described in Supplementary Table S4.
a Binary prediction of outcome using logistic regression/random forest output responses.
b Concordance-index between cox regression/random forest output responses and time to events.
c Log-rank test from Kaplan-Meier curves with a risk stratification into two groups (thresholds:
median hazard ratio for cox regression, output probability of 0.5 for random forests).
d Radiomic signature variables as defined in Aerts & Velazquez et al.21
e Using the original definition of the radiomic signature variables, and the original cox regression
coefficients and median hazard ratio trained from the Lung1 cohort in the study of Aerts &
Velazquez et al.21
f Using a revised version of the radiomic signature variables (Supplementary Methods section
2.6.2) and new cox/logistic regression coefficients trained using the current training set of this
work.
g Using a revised version of the radiomic signature variables (Supplementary Methods section
2.6.2) and a random forest classifer trained using the current training set of this work.
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Figure 4. Risk assessment of tumour outcomes. (a) Probability of occurrence of
events (locoregional recurrence, distant metastases, death) for each patient of the testing set
(H&N3 and H&N4; n = 106) as determined by the random forest classifiers built using the
training set (H&N1 and H&N2; n = 194). The output probability of occurrence of events of
random forests allows for risk stratification; for example, three risk groups can be defined (low,
medium, high) using probability thresholds of 1
3
and 2
3
. (b)Kaplan-Meier curves of the testing
set using a risk stratification into two groups as defined by a random forest output probability
threshold of 0.5. All curves have significant prognostic performance, thus demonstrating the
possibility of outcome-specific risk assessment in head-and-neck cancer. (c) Kaplan-Meier
curves of the testing set using a risk stratification in three groups as defined by random forest
output probability thresholds of 1
3
and 2
3
. Some pair of curves have significant prognostic
performance, thus demonstrating the possibility of risk stratification into multiple groups for
treatment escalation/personalization in head- and-neck cancer.
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Discussion
Increasing evidence suggests that the genomic heterogeneity of aggressive tu-
mours could translate into intratumoural spatial heterogeneity exhibited at the
anatomical and functional scales19–21. This constitutes the central idea of the
emerging field of “radiomics”, in which large amounts of information via ad-
vanced quantitative analysis of medical images are used as non-invasive means
to characterize intratumoural heterogeneity and to reveal important prognostic
information about the cancer15–18. Ultimately, the objective is to narrow down
this extensive quantity of information into simple prediction models that can
aid in the identification of specific tumour phenotypes for improved treatment
management. In this study, we were able via advanced machine learning to
develop two prediction models combining PET/CT radiomics and clinical in-
formation for the early assessment of the risk of locoregional recurrences and
distant metastases in head-and-neck cancers.
First, we extracted a total of 1615 radiomic features from PET and CT pre-
treatment images of 300 patients with head-and-neck cancer from four different
cohorts. These features are composed of 10 intensity features, 5 shape features
and 40 textures computed using 40 different combinations of extraction parame-
ters (five isotropic voxel sizes, two quantization algorithms and four numbers of
gray levels). In general, different texture features will better represent the un-
derlying tumour biology using different extraction parameters, and the optimal
set of parameters to use is application-specific and depends on many factors such
as the clinical endpoint studied and the imaging modalities employed. Texture
optimization has the potential to enhance the predictive value of the extracted
features as Vallie`res et al.29 have previously shown, and we suggest to incorpo-
rate this step in the texture extraction workflow of future similar studies.
Univariate analysis showed that the majority of the features extracted from
both PET and CT images are significantly associated with the development of
distant metastases, suggesting that the metastatic phenotype of tumours can
be captured via quantitative image analysis. On the other hand, none of the
radiomic features were significantly associated with locoregional recurrences af-
ter multiple testing corrections with a FDR of 10 %. Although combinations
of these metrics still proved useful for prognostic risk assessment, it does reveal
the need of using other types of metrics such as radiation dose characteristics
to enhance the predictive properties of the models constructed for locoregional
recurrences. In addition to radiomic features, we also investigated the asso-
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ciation of clinical variables with the different head-and-neck cancer outcomes
studied in this work. The most significant association was found between HPV
status and locoregional recurrences, a currently known result that agrees with
other studies34,35. However, this result was obtained with only 120 of the 300
patients with available HPV status, and this variable could not be used in the
subsequent multivariable analysis.
Next, we constructed multivariable prediction models from radiomic infor-
mation alone by using the methodology developed by Vallie`res et al.29 All mod-
els were entirely produced from the defined training set of this work combining
two head-and-neck cancer cohorts (H&N1 and H&N2; n = 194). The best ra-
diomic model for locoregional recurrences (Table 1) was found to possess good
predictive properties in the defined testing set of this work combining two head-
and-neck cancer cohorts (H&N3 and H&N4; n = 106). This model is composed
of one metric extracted from PET images (GLNGLSZM: gray-level nonunifor-
mityGLSZM) and two metrics extracted from CT images (correlationGLCM and
LGZEGLSZM: low gray-level zone emphasisGLSZM). The best radiomic model
for distant metastases (Table 1) was found to possess high predictive proper-
ties in the testing set, and is composed of three metrics extracted from CT
images (LRHGEGLRLM: long run high gray level emphasisGLRLM, ZSVGLSZM:
zone size varianceGLSZM and ZSNGLSZM: zone size nonuifomityGLSZM). These
results suggest that radiomic models can be specific enough to assess the risk
of different outcomes in head-and-neck cancer. The models we developed for
locoregional recurrences and distant metastases are in fact overall different and
they capture specific tumour phenotypes. It is also noteworthy that all the se-
lected radiomic features of these two models are textural, attesting to the high
potential of textures to characterize the complexity of spatial patterns within
tumours. As mentioned earlier, aggressive tumours tend to show increased in-
tratumoural heterogeneity11–13, notably in terms of the heterogeneity in size and
intensity characteristics of the different tumour sub-regions in PET and CT im-
ages. This effect may be captured by the PET-GLNGLSZM, CT-LRHGEGLRLM,
CT-ZSVGLSZM and CT-ZSNGLSZM texture features in our radiomic models, a
result in agreement with a previous study describing the importance of zone-
size nonuniformities for the prognostic assessment of head-and-neck tumours36.
From our experience, we have observed that aggressive tumours also frequently
contain large inactive or necrotic regions of uniform intensities, suggesting that
these tumours could be rapidly increasing in size and that they could be more
at risk to metastasize, for example37–39. Here, this effect may be captured by
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the CT-CorrelationGLCM and CT-LGZEGLSZM texture features. Overall, these
results suggest that radiomic features could be useful to improve our under-
standing of the underlying biology of tumours.
We also attempted in this study to improve the predictive power of our pre-
diction models by combining radiomic variables with clinical data. The first
step of our method is based on a fast mining of radiomic variables using logistic
regression. Then, random forests40 are used as a means to combine radiomic
and clinical information into a single classifier. It would also be feasible to only
use random forests to mine the radiomic variables, but our method is advanta-
geous in terms of computation speed. Our results showed that the combination
of clinical variables with the optimal radiomic variables via random forests had
a positive impact on the prediction and prognostic assessment of locoregional
recurrences and distant metastases, although with minimal impact in the latter
case (Fig. 3, Table 1). As seen in Supplementary Table S4, this can be ex-
plained from the fact that the identified radiomic features are the strong and
dominant variables in the model for distant metastases predictions. Nonetheless,
we believe that random forests is one effective algorithm well-suited to combine
variables of different types (categorical and continuous inputs) such as clinical
and panomic tumour profile information. In general, the ongoing optimization
of machine learning techniques in radiomic applications41–43 is a step forward
to improve clinical predictions.
In this work, we also performed a comprehensive comparison of the predic-
tion/prognostic performance of radiomics versus clinical models and volumetric
variables (Table 1). Metabolic tumour volume has already been shown to be an
independent predictor of outcomes in head-and-neck cancer44, but it was also
suggested by Hatt et al.45 that heterogeneity quantification via texture analysis
may provide valuable complementary information to the tumour volume vari-
able for volumes above 10 cm3. In this study, 85 % of the patients had a gross
tumour volume greater than 10 cm3 and we consequently found that radiomic
models performed considerably better than tumour volume alone for the pre-
diction of locoregional recurrences and distant metastases. On the other hand,
clinical variables alone did not perform well on their own for distant metastases,
but they had good performance for locoregional recurrences by outperforming
radiomic models, thus suggesting that our radiomic models need to be improved
to better model locoregional recurrences.
In terms of overall survival assessment, our results indicate that the tu-
mour volume variable matched or outperformed all radiomic models thus far we
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developed or tested in this work, including a previously validated radiomic sig-
nature21,32. For one, it is unsurprising that the original radiomic signature21 did
not perform better than tumour volume, as it can be verified that all its feature
components are very strongly correlated with tumour volume: the Pearson lin-
ear coefficients between tumour volume and the four features of the signature21
were calculated to be 0.62 (Energy), 0.80 (Compactness), 0.99 (GLNGLRLM)
and 0.94 (GLNGLRLM HLH ) using the whole set of 300 patients of this study,
all with p ≪ 0.001. On the other hand, all the features forming the other ra-
diomic models developed in this work showed potential complementarity value
to tumour volume (but the models still did not perform better than tumour
volume alone for overall survival assessment): all the features of the revised
version of the radiomic signature (Supplementary Section 2.6.2) had a Pearson
linear coefficient lower than 0.5 except one (Energy), and all the variables form-
ing the final radiomic models constructed in this work (italic fonts in Table 1,
including those for locoregional recurrences and distant metastases) had linear
coefficients lower than 0.40. This suggests that overall survival may be harder
to model than specific tumour outcomes due to a larger number of confound-
ing factors being involved, and it may thus be more prone to overfitting during
training. As a consequence, tumour volume may currently be a more robust and
reproducible metric than imaging features for modeling this outcome. In the
end, the best global performance for overall survival was however obtained with
clinical variables alone. This would emphasize that clinical data remains the
important source of information to consider for the evaluation of the likelihood
of occurrence of a general outcome with many confounding factors such as over-
all survival, and that more work is required to understand how to adequately
model overall survival using radiomic features.
The optimal results in terms of predictive/prognostic performance and bal-
ance of prediction between the occurrence and non-occurrence of locoregional
recurrences and distant metastases were found in this work by constructing
models combining radiomic and clinical variables via random forests (full de-
scription of the models in Supplementary Results). Compared to the general
assessment of overall survival as in previous studies21,32, our results demonstrate
the possibility of decoding specific tumour phenotypes for the risk assessment
of specific outcomes in head-and-neck cancer. The final results obtained for
distant metastases were considerably higher than those obtained for overall sur-
vival, but those obtained for locoregional recurrences were lower albeit clinically
significant (Table 1). Also, as seen in Fig. 4 with patients of the testing set,
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the output probability of occurrence of events of our prediction models allow
to significantly separate patients into two locoregional recurrence risk groups
and into three distant metastases risk groups. The clinical impact of our results
and of the risk assessment of specific outcomes in head-and-neck cancer could
be substantial, as it could allow for a better personalization of treatments. For
example, higher radiation doses could be considered for patients at higher risks
of locoregional recurrences. For distant metastases, the chemotherapy regimens
could be strengthened for patients in the high risk group to reduce potential
metastatic invasion, and lessened for patients in the low risk group to improve
quality of life. These are hypothetical scenarios that, at the moment, are not
ready to be implemented in the clinical environment, as our models first need
to be constructed and validated on larger patient cohorts, and robust clinical
trials are required to validate their benefits on patient survival. Furthermore,
the heterogeneity of the patient cohorts used in this work including varying im-
age acquisition parameters may undermine the power of the developed models.
However, it may also improve their generalizability, and the results presented
in this study could now be useful for the generation of new hypotheses driving
future prospective studies.
Overall, we showed in this study that radiomics provide important prognos-
tic information for the risk assessment of locoregional recurrences and distant
metastases in head-and-neck cancer. In general, the combination of panomics
data into clinically-integrated prediction models should allow to more compre-
hensively assess cancer risks and could improve how we adapt treatments for
each patient. As the standardization efforts of radiomics analysis continue to
rapidly progress46,47, we can envision the clinical implementation of radiomics-
based decision-support systems in the future. Full transparency on data and
methods is the key for the progression of the field, and our research efforts needs
to include large-scale collaborations and reproducibility practices to increase the
possibility of translation of radiomics into the clinical environment48.
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Methods
Data sets availability
Our analysis was conducted on imaging and clinical data of a total of 300 H&N
cancer patients from four different institutions who received radiation alone
(n = 48, 16 %) or chemo-radiation (n = 252, 84 %) with curative intent as part
of treatment management. The median follow-up period of all patients was
43 months (range: 6-112). The Institutional Review Boards of all participat-
ing institutions approved the study. Retrospective analyses were performed in
accordance with the relevant guidelines and regulations as approved by the Re-
search Ethics Committee of McGill University Health Center (Protocol Number:
MM-JGH-CR15-50).
• The H&N1 data set consists of 92 head-and-neck squamous cell carcinoma
(HNSCC) patients treated at Hoˆpital ge´ne´ral juif (HGJ) de Montre´al, QC,
Canada. During the follow-up period, 12 patients developed a locoregional
recurrence (13 %), 16 patients developed distant metastases (17 %) and
14 patients died (15 %). This data set was used as part of the training set
of this work.
• The H&N2 data set consists of 102 head-and-neck squamous cell carci-
noma (HNSCC) patients treated at Centre hospitalier universitaire de
Sherbrooke (CHUS), QC, Canada. During the follow-up period, 17 pa-
tients developed a locoregional recurrence (17 %), 10 patients developed
distant metastases (10 %) and 18 patients died (18 %). This data set was
used as part of the training set of this work.
• The H&N3 data set consists of 41 head-and-neck squamous cell carcinoma
(HNSCC) patients treated at Hoˆpital Maisonneuve-Rosemont (HMR) de
Montre´al, QC, Canada. During the follow-up period, 9 patients developed
a locoregional recurrence (22 %), 11 patients developed distant metastases
(27 %) and 19 patients died (46 %). This data set was used as part of the
testing set of this work.
• The H&N4 data set consists of 65 head-and-neck squamous cell carci-
noma (HNSCC) patients treated at Centre hospitalier de l’Universite´ de
Montre´al (CHUM), QC, Canada. During the follow-up period, 7 patients
developed a locoregional recurrence (11 %), 3 patients developed distant
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metastases (5 %) and 5 patients died (8 %). This data set was used as
part of the testing set of this work.
All patients underwent FDG-PET/CT imaging scans within a median of 18
days (range: 6-66) before treatment. For 93 of the 300 patients (31 %), the
radiotherapy contours were directly drawn on the CT of the PET/CT scan by
expert radiation oncologists and thereafter used for treatment planning. For 207
of the 300 patients (69 %), the radiotherapy contours were drawn on a different
CT scan dedicated to treatment planning and were propagated/resampled to the
FDG-PET/CT scan reference frame using intensity-based free-form deformable
registration with the software MIM R© (MIM software Inc., Cleveland, OH).
Further information specific to each patient cohort (e.g. treatment details) is
presented in Supplementary Methods section 2.4 and Supplementary Tables S5-
S8. Pre-treatment FDG-PET/CT imaging data, clinical data, radiotherapy con-
tours (RTstruct) and MATLAB R© routines allowing to read imaging data and
their associated region-of-interest (ROI) are made available for all patients on
The Cancer Imaging Archive (TCIA)49 at: http://www.cancerimagingarchive.net.
The Research Ethics Committee of McGill University Health Center approved
online publishing of clinical and imaging data following patient anonymisation.
Sample size and division of cohorts
Patients with recurrent H&N cancer or with metastases at presentation, and
patients receiving palliative treatment were excluded from the study. Patients
that did not develop a locoregional recurrence or distant metastases during the
follow-up period and that had a follow-up time smaller than 24 months were also
excluded from the study. The four patient cohorts were then divided into two
groups to create one combined training set (H&N1 and H&N2; n = 194) and
one combined testing set (H&N3 and H&N4; n = 106). Bootstrap resampling
and stratified random sub-sampling were always performed with patients from
the training set to estimate the relevant performance metrics of interest and to
construct the final prediction models, and fully independent validation results
were computed with patients from the testing set. This precise type of division
of patient cohorts allowed to: I) Train on a combined set of different cohorts to
allow the models to take into account some institutional variability; II) Reduce
the number of testing results reported; III) Create a training set size to testing
set size ratio of approximately 2:1; and IV) Conduct partition sampling such
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that the proportion of occurrence of events (locoregional recurrences, distant
metastases) are approximately the same in the training and testing sets.
Extraction of radiomic features
Starting from the original FDG-PET/CT imaging data and associated radio-
therapy contours in DICOM format, the complete set of data was read and
transferred into MATLAB R© (MathWorks, Natick, MA) format using in-house
routines. PET images were converted to standard uptake value (SUV) maps
and CT images were kept in raw Hounsfield Unit (HU) format. In this work,
we then extracted a total of 1615 radiomic features for both the PET and CT
images from the tumour region defined by the “GTVprimary + GTVlymph nodes”
contours as delineated by the radiation oncologists of each institution. These
features can be divided into three different groups: I) 10 first-order statistics
features (intensity); II) 5 morphological features (shape); and III) 40 texture
features each computed using 40 different combinations of extraction parame-
ters.
Intensity features are computed from histograms (nbins = 100) of the in-
tensity distribution of the ROI. The features extracted in this work were the
variance, the skewness, the kurtosis, SUVmax, SUVpeak, SUVmean, the area
under the curve of the cumulative SUV-volume histogram50, the total lesion
glycolysis, the percentage of inactive volume and the generalized effective total
uptake51. Shape feature describe geometrical aspects of the ROI. The features
extracted in this work were the volume, the size (maximum tumour diameter),
the solidity, the eccentricity and the compactness.
Texture features measure intratumoural heterogeneity by quantitatively de-
scribing the spatial distributions of the different intensities within the ROI. In
this work, 9 features from the Gray-Level Co-occurrence Matrix (GLCM)52, 13
features from the Gray-Level Run-Length Matrix (GLRLM)53–55, 13 features
from the Gray-Level Size Zone Matrix (GLSZM)53–56 and 5 features from the
Neighbourhood Gray-Tone Difference Matrix (NGTDM)57 were computed. All
texture matrices were constructed using 3D analysis/26-voxel connectivity of
the tumour region resampled to a defined isotropic voxel size. For each of the
four texture types, only one matrix was computed per scan by simultaneously
taking into account the neighbouring properties of voxels in the 13 directions
of 3D space. However, the 6 voxels at a distance of 1 voxel, the 12 voxels at a
distance of
√
2 voxels, and the 8 voxels at a distance of
√
3 voxels around center
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voxels were treated differently in the calculation of the matrices to take into
account discretization length differences.
All 40 texture features from the ROI of both PET and CT volumes were
extracted using all possible combinations (40) of the following parameters:
• Isotropic voxel size (5): Voxel sizes of 1 mm, 2 mm, 3 mm, 4 mm and
5 mm.
• Quantization algorithm (2): Equal-probability (equalization of intensity
histogram) and Uniform (uniform division of intensity range) quantization
algorithms with fixed number of gray levels.
• Number of gray levels (4): Fixed number of gray levels of 8, 16, 32 and 64
in the quantized ROI.
Detailed description with supplementary references and methodology used
to extract all radiomic features is further provided in Supplementary Methods
section 2.5.
Construction of radiomic models
The construction of prediction models from the total set of radiomic features
for each of the three initial feature sets (I: PET features; II: CT features; and
III: PET and CT features) and three H&N cancer outcomes was performed
from the defined training set of this work (H&N1 and H&N2 cohorts; n = 194)
using the methodology developed in the work of Vallie`res et al.29 The process
of combining radiomic features into a multivariable model was achieved using
the logistic regression utilities of the software DREES58. The general workflow
is presented in Supplementary Fig. S5.
First, feature set reduction was performed for each of the initial feature
sets via a stepwise forward feature selection scheme in order to create reduced
feature sets containing 25 different features balanced between predictive power
(Spearman’s rank correlation) and non-redundancy (maximal information coef-
ficient59). This procedure was carried out using the Gain equation29, which is
fully detailed in Supplementary Methods section 2.2.2.
From the reduced feature sets, stepwise forward feature selection was then
carried out by maximizing the 0.632+ bootstrap AUC60,61. For a given model
order (number of combined variables) and a given reduced feature set, the fea-
ture selection step was divided into 25 experiments. In each of these exper-
iments, all the different features from the reduced set were used as different
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“starters”. For a given starting feature, 100 logistic regression models or order
2 were first created using bootstrap resampling (100 samples) for each of the re-
maining features in the reduced feature set. Then, the single remaining feature
that maximized the 0.632+ bootstrap AUC of the 100 models was chosen, and
the process was repeated up to model order 10. Finally, for each model order
of each feature set, the experiment that yielded the highest 0.632+ bootstrap
AUC was identified, and combinations of features were chosen for model orders
of 1 to 10. The whole feature selection process is pictured in Supplementary
Fig. S6.
Once optimal combinations of features were identified for model orders of
1 to 10 for all feature sets, prediction performance was estimated using the
0.632+ bootstrap AUC (100 samples). By inspecting the prediction estimates
shown in Supplementary Fig. S2, a single combination of features (i.e. model
order) potentially possessing the best parsimonious properties was then chosen
for each feature set and each outcome (identified as circles in Supplementary
Fig. S2). The final logistic regression coefficients of these selected radiomic
prediction models (3 feature sets × 3 outcomes) were then found by averaging
all coefficients computed from another set of 100 bootstrap samples. These
prediction models in their final form were thereafter directly tested in the defined
testing set of this work (H&N3 and H&N4 cohorts; n = 106).
Combination of radiomic and clinical variables
The construction of prediction models combining radiomic and clinical variables
was also carried out using the training set consisting of the combination of 194
patients from the H&N1 and H&N2 cohorts (Fig. 2). First, random forest clas-
sifiers40 containing only the following clinical variables were constructed for the
LR, DM and OS outcomes: I) Age; II) H&N type (oropharynx, hypopharynx,
nasopharynx or larynx); and III) Tumour stage. The selection of the following
best groups of tumour stage variables to be incorporated into the “clinical-only”
random forest classifiers was performed: I) T-Stage; II) N-Stage; III) T-Stage
and N-Stage; and IV) TNM-Stage. Estimation of prediction performance for
feature selection and subsequent random forest training was performed in the
training set using stratified random sub-sampling and imbalance adjustments
to account for the disproportion between the occurrence and non-occurrence of
events. Overall, the following staging variables were estimated to possess the
highest prediction performance in the training set when combined into random
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forest classifiers with Age and H&N type, and were thereafter used for the rest
of the work accordingly for each outcome: I) T-Stage and N-Stage for LR pre-
diction; II) N-Stage for DM prediction; and III) T-Stage and N-Stage for OS
prediction. Finally, the variables of the previously identified radiomic prediction
models (3 feature sets × 3 outcomes) were incorporated with the corresponding
clinical variables identified for each outcome via the separate construction of
final random forests classifiers.
Imbalance-adjustment strategy
To obtain models with predictive power equally balanced between the prediction
of occurrence of events and non-occurrence of events, an imbalance adjustment
strategy adapted from the work of Schiller et al.30 was used in this work (Sup-
plementary Fig. S4). Imbalance-adjustments become an essential part of the
training process when the proportion of instances (e.g. patients) of a given
class (e.g. occurrence of an event) is much lower than the proportion of in-
stances of the other class (e.g. non-occurrence of an event). This is the case in
this work for the proportion of locoregional recurrences, distant metastases and
death events in the training and testing sets (Fig. 2).
In this work, every time a different bootstrap sample was drawn from the
training set to construct a logistic regression or a random forest classifier, a
different ensemble of multiple balanced classifiers was used in the training pro-
cess instead of using only one unbalanced classifier. The ensemble classifier is
composed of a number of P = [N−/N+] partitions, where N− is the number
of instances from the majority class and N+ the number of instances from the
minority class in a particular bootstrap sample. The N+ instances are copied
and used in every partition, and the N− instances are randomly sampled with-
out replacement in the P partitions such that the number of instances of the
majority class is either ⌊N−/P ⌋ or ⌈N−/P ⌉ in each partition. For example, for
N− = 168 and N+ = 32, five partitions would be created: two would contain
33 instances from the majority class, three would contain 34 instances from the
majority class, and all would contain the 32 instances from the minority class.
For the logistic regression training process, a different classifier (i.e. different
coefficients) is then trained for each of the created partitions, and the final
ensemble classifier consists in the average of the corresponding coefficients from
each partition. For random forest training, each partition is used to create a
decision tree to be appended to a final forest instead of creating only one tree
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per bootstrap sample.
Random forest training
The process of random forest training inherently uses bootstrapping in order
to train the multiple decision trees of the forest. Conventionally, one differ-
ent decision tree is trained for each bootstrap sample. In this work, we used
100 bootstrap samples to train each random forest constructed from the train-
ing set (H&N1 and H&N2 cohorts; n = 194). For each bootstrap sample, the
imbalance-adjustment strategy detailed above was used such that each boot-
strap sample produced multiple decision trees (one per partition) to be appended
to a random forest. Therefore, the final number of decision trees per random
forest was dependent on the actual proportion of events in each bootstrap sam-
ple for each outcome studied. The three final random forest models developed
in this work (italic fonts in Table 1, Supplementary Table S4) were constructed
using 582, 661 and 518 decision trees for LR, DM and OS, respectively.
In addition to the imbalance-adjustment strategy adopted in this work, un-
der/oversampling of the instances in each partition of an ensemble was used to
further correct for data imbalance in the random forest training process. Un-
der/oversampling weights of the minority class of 0.5 to 2 with increments of 0.1
were tested in this work. Stratified random sub-sampling was used to estimate
the optimal weight for a given training process (and also to estimate the opti-
mal clinical staging variables to be used) in terms of the maximal average AUC,
a process randomly separating the training set of this work into multiple sub-
training and sub-testing sets (n = 10) with 2:1 size ratio and equal proportion
of events. The final random forest models developed in this work (italic fonts in
Table 1, Supplementary Table S4) used oversampling weights of 1.4, 1.6 and 1.7
(in conjunction with the previously described imbalance-adjustment strategy)
to train the decision trees of the forests for LR, DM and OS, respectively. The
overall random forest training process is pictured in Supplementary Fig. S7.
Calculation of prediction/prognostic performance metrics
In this work, all prediction models were fully trained in the defined training set
of this work (H&N1 and H&N2 cohorts; n = 194). Models were then indepen-
dently tested in the defined testing set of this work (H&N3 and H&N4 cohorts;
n = 106). Prediction performance was assessed using ROC metrics in terms of
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the AUC, sensitivity, specificity and accuracy of classification of binary clini-
cal endpoints (locoregional recurrences, distant metastases, deaths). Prognostic
performance in terms of time estimates of clinical endpoints was assessed us-
ing the concordance-index (CI)33 and the p-value obtained from Kaplan-Meier
analysis using the log-rank test between risk groups.
For prediction performance, the output of the linear combination of features
of logistic regression models was directly used to calculate the AUC with binary
outcome data. The multivariable response was then transformed into the poste-
rior probability of occurrence of an event using a logit transform to calculate the
sensitivity, specificity and accuracy of prediction using a probability threshold of
0.5. Similarly, the output probability of occurrence of an event of random forest
models was directly used to calculate the AUC with binary outcome data, and
an output probability of 0.5 was also used to calculate the remaining metrics.
For prognostic performance, the output of the linear combination of features
of cox proportional hazard regression models was directly used to calculate the
CI with time-to-event data (time elapsed between the date the treatment ended
and the date when an event occurred or the date of last-follow-up). The median
of the output of the cox regression models found in the training set was used to
separate the patients of the testing set into two risk groups for Kaplan-Meier
analysis. For random forests, the output probability of occurrence of an event
was directly used to calculate the CI with time-to-event data, and a probability
threshold of 0.5 was used to separate the patients of the testing set into two risk
groups (or 13 and
2
3 for three risk groups) for Kaplan-Meier analysis.
Code and models availability
All software code used to produce the results presented in this work is freely
shared under the GNU General Public License on the GitHub website at:
https://github.com/mvallieres/radiomics.
Notably, a single organized script allowing to run all the experiments per-
formed in this work is available, as well as a standalone MATLAB R© application
in the form of a graphical user interface (GUI) to test the final models identified
in this work on new patients.
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